Why in case of b syndrome with history of preterm labour, we are using low dose aspirin, not the low molecular weight heparin?
Reading File
Finding Sources
Searching PubMed
antiphospholipid pregnancy aspirin heparin
Searching the Web
ACR guideline antiphospholipid syndrome pregnancy low dose aspirin LMWH obstetric APS preterm delivery
Finding Sources
Assuming you mean antiphospholipid syndrome (APS):
A past preterm labour alone does not automatically justify LMWH. The choice depends on why the preterm birth happened and whether the patient meets criteria for obstetric APS or has prior thrombosis.
- Low-dose aspirin (LDA) is mainly an antiplatelet drug. It is used to lower risk of placental disease, particularly preeclampsia and placental insufficiency. It may be used in aPL-positive women who do not meet APS criteria, or for usual obstetric preeclampsia prophylaxis.
- LMWH is an anticoagulant. It is added when the risk of placental thrombosis or maternal venous/arterial thrombosis is high enough to justify daily injections and bleeding/neuraxial-anesthesia considerations.
The key distinction
| Clinical situation | Typical approach |
|---|---|
| aPL positive, but no prior thrombosis and no APS-defining obstetric event | Often no drug or LDA alone depending on risk profile |
| APS with a prior delivery before 34 weeks because of severe preeclampsia, eclampsia, or placental insufficiency | LDA + prophylactic LMWH |
| APS with recurrent early miscarriage or fetal death at/after 10 weeks | LDA + prophylactic LMWH |
| APS with previous venous or arterial thrombosis | LDA + therapeutic-dose LMWH |
So, if the history was merely spontaneous preterm labour such as from cervical insufficiency, infection, PPROM, or idiopathic preterm labour, it is not the APS obstetric criterion. LMWH has not been shown to prevent those mechanisms. Management should target the actual cause of preterm birth, while aspirin may be given only if there is a separate preeclampsia or placental-risk indication.
By contrast, a delivery before 34 weeks due to severe preeclampsia or placental insufficiency is an APS-defining obstetric event. In that setting, aspirin alone is generally inadequate if APS is confirmed: prophylactic LMWH is usually added. The textbook table states this explicitly: obstetric APS without previous thrombosis is managed with low-dose aspirin plus prophylactic LMWH. Rheumatology, 2-Volume Set (2022), Table 145.4, p. 1459.
The ACR reproductive-health guidance similarly differentiates aPL positivity without APS, where aspirin alone can be considered, from definite obstetric APS, where heparin-based treatment is considered. A recent systematic review of heparin in APS pregnancy also reflects that the evidence is directed toward placenta-mediated APS complications, not spontaneous preterm labour.
In short: aspirin is not a substitute for LMWH in confirmed obstetric APS. It is used alone when the patient has a lower-risk aPL profile or a non-APS indication for preeclampsia prevention.
Y do we use warfarin mechanical valve replin pregnancy
Reading File
Finding Sources
Searching PubMed
pregnancy mechanical heart valve warfarin
Searching the Web
2025 ESC pregnancy mechanical heart valve warfarin LMWH guideline maternal thrombosis fetal risk
With a mechanical heart valve, warfarin may be used during pregnancy because it is generally more dependable than LMWH at preventing mechanical-valve thrombosis.
Mechanical valves are highly thrombogenic. If the valve thromboses, it can cause acute obstruction, stroke, heart failure, and maternal death. Pregnancy itself increases clotting tendency, while LMWH doses can become inadequate because maternal weight, blood volume, and renal clearance change. LMWH can be used, but only at therapeutic twice-daily dosing with frequent anti-Xa monitoring and dose adjustment. Without this monitoring, the risk of valve thrombosis is unacceptably high.
The trade-off is:
- Warfarin crosses the placenta. It can cause miscarriage, fetal bleeding, and fetal abnormalities, especially with exposure during weeks 6 to 12.
- LMWH does not cross the placenta, so it is safer for the fetus, but may provide less reliable maternal protection against mechanical-valve clotting unless monitored very closely.
Therefore, warfarin may be chosen, especially if the mother is at high thrombosis risk, such as with a mechanical mitral valve, older-generation valve, previous valve thrombosis/systemic embolism, atrial fibrillation, or a high warfarin requirement. The 2025 ESC guidance considers continuing a vitamin K antagonist in the second and third trimesters for women at higher risk of valve thrombosis, with a change to heparin near delivery. ESC pregnancy guidance
A common principle is:
- Early pregnancy, especially weeks 6-12: consider therapeutic LMWH to avoid warfarin embryopathy, particularly if the required warfarin dose is high.
- Second and third trimester: warfarin may be resumed/continued when maternal valve-thrombosis risk outweighs fetal risks.
- Near delivery: change from warfarin to UFH or LMWH because warfarin-related fetal and maternal bleeding at delivery is dangerous.
So the short answer: we use warfarin despite fetal risk because maternal mechanical-valve thrombosis can be rapidly fatal, and warfarin prevents it more reliably than inadequately monitored LMWH. This is always an individualized decision by a cardio-obstetric team. Creasy & Resnik’s Maternal-Fetal Medicine, “Pregnancy in Patients with Artificial Heart Valves,” pp. 1637-1638.
How come beya hcg and tah both r similar
Reading File
Finding Sources
Searching PubMed
hCG TSH receptor pregnancy
Searching the Web
hCG TSH structural similarity common alpha subunit TSH receptor pregnancy
β-hCG and TSH are similar because both are glycoprotein hormones with a shared α-subunit.
They belong to the same hormone family:
- TSH
- hCG
- LH
- FSH
Each hormone has two protein parts:
- α-subunit: common and essentially the same in all four
- β-subunit: different, and gives receptor specificity and the main biologic action
So:
- TSH = common α + TSH-specific β
- hCG = common α + hCG-specific β
Because hCG has structural similarity to TSH, very high hCG levels can weakly stimulate the TSH receptor in the thyroid.
That is why in early pregnancy, especially with hyperemesis gravidarum, multiple pregnancy, or molar pregnancy where hCG is very high, you can see:
- low TSH
- mildly high free T4/T3
- transient gestational thyrotoxicosis
But hCG is not identical to TSH. Its β-subunit makes it act mainly at the LH/hCG receptor to maintain the corpus luteum in early pregnancy. Its stimulation of the TSH receptor is only a weak cross-reaction, important mainly at very high concentrations. Scott-Brown’s Otorhinolaryngology, “The thyroid axis,” lines 7523-7542.
A review of hCG biology describes the common α-subunit relationship among hCG, TSH, LH, and FSH.
This is a shared conversation. Sign in to Orris to start your own chat.